EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Pivotal Phase 3 Theranostic Trials: Future Indications

Wolfgang P Fendler, Michael S Hofman, David Kersting, Jeremie Calais, Thomas A Hope

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.269486 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Wolfgang P Fendler und 4 weiteren Autor:innen. Beteiligte Einrichtung: German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany; wolfgang.fendler@uk-essen.de. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Theranostic Nanomedicine. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are several ongoing phase 3 randomized trials involving radiopharmaceutical therapies (RPTs), which are expected to provide practice-changing evidence in the coming years. This review covers ongoing pivotal phase 3 trials designed to expand applications for RPTs. Trials such as PSMAcTION, STAMPEDE2, PSMA-DC, and PSMAddition focus on prostate-specific membrane antigen-directed treatments for patients with prostate cancer. NETTER-3, ACTION-1, and COMPOSE evaluate somatostatin receptor-targeted radiopharmaceuticals in individuals with neuroendocrine neoplasms. Expansion of phase 3 registration trials has been driven by increased industry investment. Ongoing RPT phase 3 trials serve as hybrids, merging nuclear medicine procedures for imaging and drug application with oncology-driven standards of care and endpoint definitions. Despite the challenges associated with this integration, phase 3 RPT trials present an opportunity to revolutionize future cancer care by introducing and expanding the use of image-guided RPT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicTheranostic NanomedicineHumansRadiopharmaceuticalsMaleNeuroendocrine TumorsProstatic Neoplasms

Stichwörter der Autor:innen

clinical trialphase 3prospectivetheranostic

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany; wolfgang.fendler@uk-essen.de.
  • German Cancer Research Center, Essen, Germany.
  • Department of Nuclear Medicine, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
  • Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
  • German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany.

Förderung

  • NCI NIH HHS

Zitieren

APA

Fendler, W. P., Hofman, M. S., Kersting, D., Calais, J., & Hope, T. A. (2026). Pivotal Phase 3 Theranostic Trials: Future Indications. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269486

Vancouver

Fendler WP, Hofman MS, Kersting D, Calais J, Hope TA. Pivotal Phase 3 Theranostic Trials: Future Indications. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.269486

BibTeX
@article{Fendler2026,
  author = {Fendler, Wolfgang P and Hofman, Michael S and Kersting, David and Calais, Jeremie and Hope, Thomas A},
  title = {Pivotal Phase 3 Theranostic Trials: Future Indications},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.269486}
}
Kostenlos starten →